Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Lee, Kathy ^a   Vivithanaporn, Pornpun ^b,c   Siemieniuk, Reed A ^a   Krentz, Hartmut B ^a,d   Maingat, Ferdinand ^b   Gill, M John ^a,d,e   Power, Christopher ^a,b,e  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CD4 ANTIGEN; CD8 ANTIGEN; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE DURATION; DRUG FATALITY; DRUG INDICATION; EPILEPSY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNE STATUS; IN VITRO STUDY; INHIBITION KINETICS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; PERIPHERAL NEUROPATHY; PRESCRIPTION; SEIZURE; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; CELL CULTURE; CELL PROLIFERATION; COHORT ANALYSIS; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TIME; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTICONVULSANTS; ANTIGENS, CD4; ANTIGENS, CD8; CALCIUM CHANNEL BLOCKERS; CELL PROLIFERATION; CELLS, CULTURED; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SODIUM CHANNEL BLOCKERS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID; VIRUS REPLICATION;

EID: 77953579619     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-44     Document Type: Article

References (31)

1. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007, 4(1):75-83. 10.1016/j.nurt.2006.10.003, 17199018.
2. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature medicine 2004, 10(7):685-692. 10.1038/nm1074, 15229516.
3. Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008, 22(9):739-760. 10.2165/00023210-200822090-00003, 18698874.
4. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002, 22(1):27-39. 10.1055/s-2002-33046, 12170391.
5. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS drugs 2005, 19(4):325-334. 10.2165/00023210-200519040-00005, 15813646.
6. Kellinghaus C, Engbring C, Kovac S, Moddel G, Boesebeck F, Fischera M, Anneken K, Klonne K, Reichelt D, Evers S, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 2008, 17(1):27-33. 10.1016/j.seizure.2007.05.017, 17618132.
7. Pascual-Sedano B, Iranzo A, Marti-Fabregas J, Domingo P, Escartin A, Fuster M, Barrio JL, Sambeat MA. Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Archives of neurology 1999, 56(5):609-612. 10.1001/archneur.56.5.609, 10328257.
8. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biological psychiatry 2003, 54(3):307-316. 10.1016/S0006-3223(03)00318-4, 12893106.
9. Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, Straube ME, Schielke E. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Journal of neurology 2004, 251(10):1260-1266. 10.1007/s00415-004-0529-6, 15503108.
10. Halman MH, Worth JL, Sanders KM, Renshaw PF, Murray GB. Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. The Journal of neuropsychiatry and clinical neurosciences 1993, 5(4):430-434.
11. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003, 60(9):1508-1514.
12. Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000, 54(7):1404-1407.
13. Liedtke MD, Lockhart SM, Rathbun RC. Anticonvulsant and antiretroviral interactions. The Annals of pharmacotherapy 2004, 38(3):482-489. 10.1345/aph.1D309, 14970370.
14. Robinson B, Turchan J, Anderson C, Chauhan A, Nath A. Modulation of human immunodeficiency virus infection by anticonvulsant drugs. Journal of neurovirology 2006, 12(1):1-4. 10.1080/13550280500516278, 16595368.
15. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Dewey R, Chesebro B. Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Current topics in microbiology and immunology 1995, 202:89-104.
16. Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, Holden J, McArthur JC, Power C. Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. Journal of virology 2000, 74(16):7211-7220. 10.1128/JVI.74.16.7211-7220.2000, 112242, 10906175.
17. Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. The Canadian journal of neurological sciences 2005, 32(2):201-204.
18. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clinics in liver disease 2003, 7(2):475-499. 10.1016/S1089-3261(03)00023-0, 12879995.
19. Cloyd MW, Lynn WS, Ramsey K, Baron S. Inhibition of human immunodeficiency virus (HIV-1) infection by diphenylhydantoin (dilantin) implicates role of cellular calcium in virus life cycle. Virology 1989, 173(2):581-590. 10.1016/0042-6822(89)90569-2, 2574518.
20. Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Canadian journal of psychiatry 2001, 46(4):359-362.
21. Maggi JD, Halman MH. The effect of divalproex sodium on HIV replication in vivo. The Journal of neuropsychiatry and clinical neurosciences 2007, 19(3):326-330.
22. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J, Moore RD, Gange SJ, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. The Journal of infectious diseases 2007, 195(6):833-836. 10.1086/511823, 17299713.
23. Romanelli F, Pomeroy C. Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Current pharmaceutical design 2003, 9(18):1433-1439. 10.2174/1381612033454676, 12769723.
24. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366(9485):549-555. 10.1016/S0140-6736(05)67098-5, 1894952, 16099290.
25. La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol 2001, 8(1):71-75. 10.1046/j.1468-1331.2001.00157.x, 11509084.
26. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (London, England) 2008, 22(10):1131-1135.
27. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Molecular cancer therapeutics 2006, 5(9):2203-2210. 10.1158/1535-7163.MCT-05-0480, 16985053.
28. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Molecular cancer therapeutics 2005, 4(12):1912-1922. 10.1158/1535-7163.MCT-05-0184, 16373706.
29. Ances BM, Letendre S, Buzzell M, Marquie-Beck J, Lazaretto D, Marcotte TD, Grant I, Ellis RJ. Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of neurovirology 2006, 12(5):403-406. 10.1080/13550280600981695, 17065134.
30. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006, 66(6):919-921. 10.1212/01.wnl.0000204294.28189.03, 16510768.
31. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Delfraissy JF, Lambotte O. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (London, England) 2008, 22(10):1125-1129.